Abstract：Objective To observe the effects of pabolizumab on T lymphocyte subsets and serum soluble MHC-1 chain related protein A(sMICA)levels in patients with non-small cell lung cancer(NSCLC). Methods 140 patients with NSCLC were treated in our hospital.They were divided by random number table method,70 patients in the control group were treated with AP regimen,and 70 patients in the observation group were treated with palizol.The clinical efficacy of the two groups was compared,the peripheral blood T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)were detected,the serological indicators[squamous cell carcinoma associated antigen(SCC-Ag),carcinoembryonic antigen(CEA),sMICA,Transforming growth factor β1(TGF-β1),Vascular endothelial growth factor(VEGF)] were detected,and the adverse reactions of the two groups were recorded. Results The DCR of the observation group was 84.29%,which was higher than the control group's 67.14%(P<0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+ in observation group were and,which were higher than those in control group and.CD8+ level in observation group was,lower than that in control group,P<0.05.After treatment,the serum levels of SCC-Ag,CEA and sMICA in the observation group were and pg/mL.It was lower than that of control group,P<0.05.After treatment,the levels of TGF-β1 and VEGF in serum were and,which were lower than those in control group(29.03±4.12)μg/L and(377.14±35.98)ng/L,P<0.05.The incidence of adverse reactions was similar between the two groups(P>0.05). Conclusion Pabolizumab can regulate the level of T lymphocyte subsets,reduce the level of tumor markers and serum sMICA in non-small cell lung cancer NSCLC,and has good efficacy and safety.
李兰菊, 徐恩松, 李文明, 张楠. 帕博利珠单抗对非小细胞肺癌患者T淋巴细胞、血清sMICA水平的影响[J]. 哈尔滨医药, 2025, 45(4): 17-19.
Li Lanju, Xu Ensong, Li Wenming, Zhang Nan. Effects of Pabolizumab on T Lymphocyte and Serum sMICA Levels in Patients with Non-small Cell Lung Cancer. journal1, 2025, 45(4): 17-19.
2025, Vol. 45 
